Impact Factor
3.77
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
3.81
1,454 total citations
h5-index
34
h5 depth signal
Cited share
80.7%
317 of 393
Total citations
1,454
Citation footprint
Metric signal
3.70
External metric anchor
Self-citation
1.2%
18 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
655
Italy
521
United Kingdom
156
Germany
117
Greece
106
Citing Fields of Research
Diabetes
202
Psychiatry
188
Cardiology
166
Oncology
159
Hematology
127
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
6,158
Articles tracked across the journal lifetime
Indexed publication set
393
317 cited publications
Last 12 months
199
16.6 publications/month
Open access share
14.6%
29 OA publications in the last year
Leading citing country
United States
655 citing publications
Leading citing field
Diabetes
202 citing publications
Latest tracked publication
19 October 2026
10 recent records available
Coverage & Indexing History
v1n1, Nov. 1999-
v1n1, Nov. 1999-
Active Coverage
Research Focus & Classification
Indexed Subjects
Hematology
Cardiology
Diabetes
Musculoskeletal Disorders
Antibiotic & Antibacterial Agents
Digestive Disorders
Anesthetic & Pain Medicine
Broad Categories
Pharmacology
Hematology
Urology
Diabetes
Musculoskeletal Disorders
Cardiology
Psychiatry
Endocrine Therapy
MeSH Descriptors
Drug Evaluation
Drug Therapy
Pharmacology
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1080/14656566.2026.2749640
Open DOI
Persisting challenges for antioxidants use in treatment of male infertility
02
DOI 10.1080/14656566.2026.2749642
Open DOI
Current perspectives on targeted and combination pharmacotherapy for low-grade serous ovarian cancer
03
DOI 10.1080/14656566.2026.2750247
Open DOI
Gastrointestinal stromal tumors: can we do better than sunitinib in the second line?
1. Gastrointestinal stromal tumours are the most common mesenchymal tumours of the gastrointestinal tract [1]. They are most commonly found in the stomach (about 50% of cases), less frequently in t...
04
DOI 10.1080/14656566.2026.2749637
Open DOI
Current perspectives in the pharmacological management of cutaneous and mucosal leishmaniasis
05
06
DOI 10.1080/14656566.2026.2749634
Open DOI
CURGET: a combination of common-use polyphenols plus trimetazidine as metabolic therapy for cancer: a theoretical proposal
07
DOI 10.1080/14656566.2026.2749638
Open DOI
New and emerging pharmacological solutions for Behçet’s syndrome
1. Behçet’s syndrome (BS) is a chronic, multisystem inflammatory disorder characterized by recurrent oral and genital ulcers, skin lesions, and uveitis. The disease may also involve the joints, gas...
08
DOI 10.1080/14656566.2026.2749647
Open DOI
Current perspectives on the pharmacotherapeutic management of insomnia in Veterans
Insomnia is a highly prevalent sleep disorder among Veterans and frequently co-occurs with post-traumatic stress disorder (PTSD), depression, chronic pain, and substance use disorders. This review synthesizes the current evidence on phar...
09
DOI 10.1080/14656566.2026.2749645
Open DOI
Obesity: oral therapy for those afraid of needles
10
DOI 10.1080/14656566.2026.2749635
Open DOI
Positioning gestrinone among the progestins: a narrative review of pharmacology, efficacy, safety, and tolerability
1. Gestrinone (R-2323) is a synthetic androgenic progestin derived from 19-nortestosterone, with a multireceptor profile (antigonadotropic, antiprogestational, androgenic and antiestrogenic actions...
Bibliographical & Catalog Notes
Title from cover.
Vol. 1 complete in seven issues.
Also issued online.
v. 1, no. 1 (Nov. 1999)20010501 Notice not published Printed on acid-free paper